Licensees and MSCs, page-3

@pfeifer1982
Thanks for the input, especially for the numbers, I should have looked

Yes the Expected label population is rather larger.

I've had a another read in light of the info you've provided at the price per dose I used, it's now clear that range of prices I read about from the Decision Resources Group is for the US but using the estimated lowest EU peak sales per year using a 3% royalty the numbers are still much better than I suspected, about double.

You wrote;
"There are similar indications that Cx601 may be able to address (credit to Sanders on seekingalpha.com):

• Rectovaginal fistulas in CD,
• Enterocutaneous fistulas in CD,
• Complex anal fistulas in non-CD,
• Intestinal ulcers in CD and
• Intestinal ulcers in Ulcerative Colitis."

That helps me see why MSB retained the trial to;
"Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease"

Prochymal could address a much larger group of people.